Sun Pharma Advanced Research Valuation
Is 532872 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 532872 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 532872's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 532872's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 532872?
Other financial metrics that can be useful for relative valuation.
What is 532872's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹73.18b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 65.3x |
Enterprise Value/EBITDA | -18x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 532872's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.2x | ||
WOCKPHARMA Wockhardt | 2.7x | n/a | ₹85.2b |
STAR Strides Pharma Science | 4x | 112.8% | ₹81.5b |
500126 Procter & Gamble Health | 9.8x | n/a | ₹78.8b |
GLS Glenmark Life Sciences | 4.4x | 13.1% | ₹101.7b |
532872 Sun Pharma Advanced Research | 22.1x | n/a | ₹73.2b |
Price-To-Book vs Peers: 532872 is expensive based on its Price-To-Book Ratio (22.1x) compared to the peer average (5.2x).
Price to Earnings Ratio vs Industry
How does 532872's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Book vs Industry: 532872 is expensive based on its Price-To-Book Ratio (22.1x) compared to the Indian Pharmaceuticals industry average (3.5x).
Price to Book Ratio vs Fair Ratio
What is 532872's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 22.1x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 532872's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.